Other gastrointestinal adverse event (e.g., nausea, vomiting, and constipation), and nervous system toxicities (e.g., headache and peripheral neuropathy) were also numerically less frequent than those reported with HER2-targeted therapy combined with chemotherapy [2]. This evidence concerns the gene ERBB2 and peripheral neuropathy.